CMV regimen
|
WikiDoc Resources for CMV regimen |
|
Articles |
|---|
|
Most recent articles on CMV regimen Most cited articles on CMV regimen |
|
Media |
|
Powerpoint slides on CMV regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CMV regimen at Clinical Trials.gov Clinical Trials on CMV regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CMV regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CMV regimen Discussion groups on CMV regimen Patient Handouts on CMV regimen Directions to Hospitals Treating CMV regimen Risk calculators and risk factors for CMV regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CMV regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:MCV; CMV
Overview
CMV regimen refers to a regimen consisting of cisplatin , methotrexate,and vinblastine used to treat advanced bladder carcinoma.[1]
Regimen
CCisplatin
MMethotrexate
VVinblastine
Indications
- Transitional bladder carcinoma.[1]
References
- ↑ 1.0 1.1 Paz-Ares L, Lianes P, Díaz-Puente M, Rivera F, Passas J, Costas P; et al. (1993). "CMV front-line chemotherapy in transitional bladder carcinoma". Ann Oncol. 4 (2): 147–50. PMID 8448083.